{"id":1826,"date":"2024-07-24T10:18:45","date_gmt":"2024-07-24T10:18:45","guid":{"rendered":"https:\/\/www.arcgroup.io\/oxford\/?p=1826"},"modified":"2024-08-01T10:46:33","modified_gmt":"2024-08-01T10:46:33","slug":"oxford-biodynamics-shortlisted","status":"publish","type":"post","link":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/","title":{"rendered":"Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy."},"content":{"rendered":"\n\n
\n\t\n\t\t\n\t\t\t<\/use>\n\t\t<\/svg>\n\t\tBack to Community\t<\/a>\n<\/div>\n\n\n\n
\n
\n \n \n \n <\/picture>\n\n <\/div>\n<\/section>\n\n\n\n

Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy<\/h2>\n\n\n\n

Oxford BioDynamics, a precision clinical diagnostics company, based at ARC Oxford, has formed a strategic consortium which has been shortlisted for the UK Government\u2019s Checkpoint Inhibitor Response Research Platform (CIRRP) award call for biomarker development around immunotherapies of cancer. If successful, the consortium\u2019s proposal will provide NHS patients with access to Oxford BioDynamics\u00a0EpiSwitch CiRT<\/a>\u00a0(Checkpoint inhibitor Response Test).<\/p>\n\n\n\n

CIRRP is a \u00a39 million initiative aimed at putting the UK at the forefront of cancer treatment, that was announced by The Medical Research Council and the Office for Life Sciences, part of the Department of Health and Social Care and the Department for Science, Innovation and Technology earlier this year.<\/p>\n\n\n\n

Oxford BioDynamics consortium consists of world leading experts in molecular epigenetics at the University of Oxford, in clinical metabolomics and lipidomics at the University of Birmingham, and in cancer treatment with Imperial College Healthcare NHS Trust and Norfolk and Norwich University NHS Trust.<\/p>\n\n\n\n

If the consortium\u2019s proposal is successful, NHS patients with colorectal, prostate, breast, ovarian or lung cancer would be prospectively evaluated with CiRT and together with their clinical outcomes and individual genetic, epigenetic and metabolic states used to offer mechanistic insights into their immune systems and clinical outcomes.<\/p>\n\n\n\n

Cancer does not exist in isolation. The most successful approaches for treating cancer will need to consider the larger systemic picture, comprising a combination of the tumour, its interaction with its environment, the immune system, and a patient\u2019s genome and epigenome. The EpiSwitch\u00ae CiRT is a first-of-its-kind blood test that accurately predicts an individual cancer patient’s therapeutic response to immune checkpoint inhibitors (ICIs), providing unique benefits for physicians in treatment planning and navigating complex decisions.[3,4]<\/sup> <\/p>\n\n\n\n

With a special award from the Partnership for Accelerating Cancer Treatment (PACT), Washington DC, OBD has developed the prognostic HiRT, demonstrating over 85% accuracy for the first 60 participants in the independent validation cohort. When combined with CiRT calls for response\/non-response to ICI, it offers highly specific prospective identification of patients who are likely to 1) respond to ICI therapy and 2) accurately identify patients likely to exhibit an HPD response to ICI treatment, both extremely useful for clinical patient management and potentially leading to reduced costs, socioeconomic benefits and improved patient outcome.<\/p>\n\n\n\n

Professor E. Jane Mellor, Department of Biochemistry, University of Oxford<\/strong>, said: \u201cIt is a real privilege to be involved in this potentially transformative initiative, to work with visionary clinicians, entrepreneurs and basic scientists, and to see how this disruptive technology, which combines epigenetics and metabolomics, is being applied for the benefit of patients within the NHS.\u201d<\/em><\/p>\n\n\n\n

You can read the full new article here<\/a><\/em>.<\/p>\n\n\n

\n
\n
\n
\n \n

More News<\/h3>\n <\/div>\n
\n \n View all news →\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n \n
\n\t
\n\t\t\n\t\t
\n\t\t\t\n\t\t\t\t \n \n \n <\/picture>\n\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t\n\t\t
\n\t\t\t\n\t\t\t\tAccession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n
\n\t
\n\t\t\n\t\t
\n\t\t\t\n\t\t\t\t \n \n \n <\/picture>\n\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t\n\t\t
\n\t\t\t\n\t\t\t\tChildbase Partnership announces new Garsington Road day nursery opening at ARC Oxford\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n
\n\t
\n\t\t\n\t\t
\n\t\t\t\n\t\t\t\t \n \n \n <\/picture>\n\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t\n\t\t
\n\t\t\t\n\t\t\t\tOxa Raises $103m in Series D First Close to supercharge Industrial Mobility Automation\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n <\/div>\n <\/div>\n <\/section>\n","protected":false},"excerpt":{"rendered":"

Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy Oxford BioDynamics, a precision clinical diagnostics company, based at ARC Oxford, has formed a strategic consortium which has been shortlisted for the UK Government\u2019s Checkpoint Inhibitor Response Research Platform (CIRRP) award call for biomarker development around immunotherapies of cancer. If successful, the consortium\u2019s […]<\/p>\n","protected":false},"author":5,"featured_media":1828,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[22,30],"tags":[4276,6210],"class_list":["post-1826","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-corporate","tag-science-and-innovation","tag-life-science-and-health"],"acf":[],"yoast_head":"\nOxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy. - ARC Oxford<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy. - ARC Oxford\" \/>\n<meta property=\"og:description\" content=\"Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy Oxford BioDynamics, a precision clinical diagnostics company, based at ARC Oxford, has formed a strategic consortium which has been shortlisted for the UK Government\u2019s Checkpoint Inhibitor Response Research Platform (CIRRP) award call for biomarker development around immunotherapies of cancer. If successful, the consortium\u2019s […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/\" \/>\n<meta property=\"og:site_name\" content=\"ARC Oxford\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-24T10:18:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-01T10:46:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/07\/oxford-biodynamics-e1721816130314.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"399\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"rebeccabethwaite\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"rebeccabethwaite\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/\"},\"author\":{\"name\":\"rebeccabethwaite\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57\"},\"headline\":\"Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy.\",\"datePublished\":\"2024-07-24T10:18:45+00:00\",\"dateModified\":\"2024-08-01T10:46:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/\"},\"wordCount\":459,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/07\/oxford-biodynamics-e1721816130314.jpg\",\"keywords\":[\"Science and innovation\",\"Life science and Health\"],\"articleSection\":[\"News\",\"Corporate\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/\",\"name\":\"Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy. - ARC Oxford\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/07\/oxford-biodynamics-e1721816130314.jpg\",\"datePublished\":\"2024-07-24T10:18:45+00:00\",\"dateModified\":\"2024-08-01T10:46:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#primaryimage\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/07\/oxford-biodynamics-e1721816130314.jpg\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/07\/oxford-biodynamics-e1721816130314.jpg\",\"width\":900,\"height\":399,\"caption\":\"oxford biodynamics at ARC Oxford\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.arcgroup.io\/oxford\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"name\":\"ARC Oxford\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"alternateName\":\"ARC Oxford\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\",\"name\":\"ARC Oxford\",\"alternateName\":\"ARC Oxford\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"width\":2084,\"height\":2084,\"caption\":\"ARC Oxford\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57\",\"name\":\"rebeccabethwaite\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g\",\"caption\":\"rebeccabethwaite\"},\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/rebeccafrost\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy. - ARC Oxford","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/","og_locale":"en_US","og_type":"article","og_title":"Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy. - ARC Oxford","og_description":"Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy Oxford BioDynamics, a precision clinical diagnostics company, based at ARC Oxford, has formed a strategic consortium which has been shortlisted for the UK Government\u2019s Checkpoint Inhibitor Response Research Platform (CIRRP) award call for biomarker development around immunotherapies of cancer. If successful, the consortium\u2019s […]","og_url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/","og_site_name":"ARC Oxford","article_published_time":"2024-07-24T10:18:45+00:00","article_modified_time":"2024-08-01T10:46:33+00:00","og_image":[{"width":900,"height":399,"url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/07\/oxford-biodynamics-e1721816130314.jpg","type":"image\/jpeg"}],"author":"rebeccabethwaite","twitter_card":"summary_large_image","twitter_misc":{"Written by":"rebeccabethwaite","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#article","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/"},"author":{"name":"rebeccabethwaite","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57"},"headline":"Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy.","datePublished":"2024-07-24T10:18:45+00:00","dateModified":"2024-08-01T10:46:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/"},"wordCount":459,"commentCount":0,"publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/07\/oxford-biodynamics-e1721816130314.jpg","keywords":["Science and innovation","Life science and Health"],"articleSection":["News","Corporate"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/","url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/","name":"Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy. - ARC Oxford","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#primaryimage"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/07\/oxford-biodynamics-e1721816130314.jpg","datePublished":"2024-07-24T10:18:45+00:00","dateModified":"2024-08-01T10:46:33+00:00","breadcrumb":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#primaryimage","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/07\/oxford-biodynamics-e1721816130314.jpg","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/07\/oxford-biodynamics-e1721816130314.jpg","width":900,"height":399,"caption":"oxford biodynamics at ARC Oxford"},{"@type":"BreadcrumbList","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/07\/24\/oxford-biodynamics-shortlisted\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arcgroup.io\/oxford\/"},{"@type":"ListItem","position":2,"name":"Oxford BioDynamics shortlisted for a strategic Government initiative to improve cancer immunotherapy."}]},{"@type":"WebSite","@id":"https:\/\/www.arcgroup.io\/oxford\/#website","url":"https:\/\/www.arcgroup.io\/oxford\/","name":"ARC Oxford","description":"","publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"alternateName":"ARC Oxford","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arcgroup.io\/oxford\/#organization","name":"ARC Oxford","alternateName":"ARC Oxford","url":"https:\/\/www.arcgroup.io\/oxford\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","width":2084,"height":2084,"caption":"ARC Oxford"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57","name":"rebeccabethwaite","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g","caption":"rebeccabethwaite"},"url":"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/rebeccafrost\/"}]}},"_links":{"self":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/1826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/comments?post=1826"}],"version-history":[{"count":0,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/1826\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media\/1828"}],"wp:attachment":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media?parent=1826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/categories?post=1826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/tags?post=1826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}